Research programme: Parkinson's disease therapeutics - Amicus Therapeutics/Biogen
Latest Information Update: 04 Nov 2017
At a glance
- Originator Amicus Therapeutics; Biogen Idec
- Developer Amicus Therapeutics; Biogen
- Class Small molecules
- Mechanism of Action Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Parkinson's-disease in USA
- 10 Sep 2013 Early research in Parkinson's disease in USA (unspecified route)